Loading data for ANL — first visit, this takes a few seconds.
Adlai Nortye Ltd. (ANL)
NasdaqGM: ANL
· Echtzeitkurs · USD
12.86
-0.23 (-1.76%)
Zum Schluss: Aug 18, 2026, 3:59 PM
Adlai Nortye Ltd. (ANL) Stock Price, Analysis & Data
-1.76% (1D)
| Geld | 9.29 |
| Marktkapitalisierung | 911.87 Mio |
| Umsatz (TTM) | 5 Mio |
| Nettogewinn (TTM) | -35.53 Mio |
| Beta | 1.12 |
| EPS (ttm) | -0.7 |
| KGV (TTM) | n/a |
| Forward-KGV | -46.68 |
| KBV (TTM) | -68.08 |
| KUV (TTM) | 182.37 |
| Earnings Date | n/a |
| Brief | 16.89 |
| Volumen | 78,430 |
| Ø Vol. (20D) | 180,843 |
| Eröffnung | 13.18 |
| Vortagesschluss | 13.09 |
| Tagesspanne | 12.52 - 13.18 |
| 52-Wk Range | 0.88 - 17.25 |
| Analyst | n/a |
| Kursziel | n/a |
| Dividenden | n/a |
| Ex-Dividenden-Datum | n/a |
Über ANL
Adlai Nortye Ltd., a clinical-stage company, together with its subsidiaries, engages in the research and develops pharmaceutical products. Its product pipeline comprises AN0025, a small molecule EP4 antagonist which is in phase Ib and radiotherapy/chemoradiotherapy combination for the treatment of rectum cancer and esophageal cancer; and phase II trial for patients with moderate to high-risk rectal cancer. The company also develops AN9025, an ora...
Branche Biotechnology
Sektor Healthcare
IPO Datum Sep 29, 2023
Mitarbeiter 109
Börse NasdaqGM
Tickersymbol ANL
Website https://www.adlainortye.com
Finanzielle Entwicklung
Im Jahr 2025 betrug der Umsatz von Adlai Nortye 5 Mio, ein Anstieg von undefined% im Vergleich zum Vorjahr (0). Der Gewinn lag bei -35.53 Mio, ein Rückgang von -31.5 %.
Finanzberichte
Seite 1 von 2